Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing ertapenem

06.12.2021 1783 views

Based on a review of the available data obtained from EudraVigilance and the literature, PRAC considers that the degree of causal relationship between the occurrence of encephalopathy and the use of medicinal products containing ertapenem (ertapenem) is at least possible, and that recovery in patients with renal impairment may be prolonged.

PRAC agreed that all registration certificate holders of medicinal products containing ertapenem must, within two months of the publication of the PRAC recommendation , make changes to the instructions for medical use.

Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).

Section “Special warnings and precautions for use”

Encephalopathy

Encephalopathy has been reported with the use of ertapenem (see the section “Adverse reactions”). If encephalopathy caused by ertapenem is suspected (for example, myoclonus, seizures, altered mental status, depressed level of consciousness), discontinuation of ertapenem should be considered. Patients with renal impairment have a higher risk of developing encephalopathy caused by ertapenem, which may prolong the duration of treatment.

“Adverse reactions” section

Adults aged 18 years and older

Nervous system disorders: encephalopathy (see section “Special warnings and precautions for use”) with the frequency “Not known”

Перелік лікарських засобів, що містять ertapenem і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 25.11.2021)

For the analysis of published information, the applicant must use the original text available at the link: